SOURCE: annual_report_text (1).txt
CHUNK: 707 of 1106
SIZE: 600 characters
PREVIOUS: chunk_0706_annual_report_text (1).txt
NEXT: chunk_0708_annual_report_text (1).txt
------------------------------
, the net 
financial result (loss) was EUR -5.2 million 
(2022: EUR -5.4 million expenses), primarily 
composed of: Realised and un-realised exchange gains 
and losses for a net loss of -3.4 million, interest paid on debts and lease liabilities for 
EUR -1.3 million, and an impact from the 
application of hyperinflation accounting (IAS 
29) on the result and non-monetary position 
of the subsidiary in Argentina for EUR 2.0 
million. Partially compensated by interest revenues 
on bank accounts and investment bonds in 
relation to proton therapy projects for EUR 
1.7 million for the Proton Thera